SK Biopharmaceuticals Co., Ltd.
326030
Kedudukan dalam Saham
#3978
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Harga Saham
$52.48
Modal Pasaran
$4.11B
Perubahan (1 hari)
3.55%
Perubahan (1 tahun)
-26.12%
Negara
KR
Perdagangan SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
Margin Operasi untuk SK Biopharmaceuticals Co., Ltd. (326030)
Margin Operasi pada October 2026 TTM: 35.20%
Menurut laporan kewangan dan harga saham terkini SK Biopharmaceuticals Co., Ltd., margin operasi semasa (TTM) ialah 35.20%. Pada akhir 2024, margin operasi syarikat ialah 17.59%.
Sejarah Margin Operasi untuk SK Biopharmaceuticals Co., Ltd. dari 2011 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | 35.20% | 21.97% |
| 2025 | 28.86% | 64.07% |
| 2024 | 17.59% | -266.41% |
| 2023 | -10.57% | -80.15% |
| 2022 | -53.24% | -400.11% |
| 2021 | 17.74% | -101.93% |
| 2020 | -921.18% | 1,339.57% |
| 2019 | -63.99% | -99.49% |
| 2018 | -12,660.28% | 10,924.28% |
| 2017 | -114.84% | 79.07% |
| 2016 | -64.13% | 16.11% |
| 2015 | -55.23% | 1.96% |
| 2014 | -54.17% | -25.84% |
| 2013 | -73.04% | 5.12% |
| 2012 | -69.48% | 7.57% |
| 2011 | -64.59% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -98.90% |
US
|
|
| -149.01% | -104.23% |
US
|
|
| 25.57% | -99.27% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.18% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.